Skip to main content

Hereditary Deficiency of C1 Inhibitor and Angioedema

  • Living reference work entry
  • First Online:
Encyclopedia of Medical Immunology

Definition

C1 inhibitor (C1-INH) is a serine protease inhibitor intimately involved in the regulation of the complement cascade and the contact system. Heterozygous deficiency of C1-INH is the most common cause of hereditary angioedema.

The Deficiency of C1 Inhibitor

C1-INH was first identified in the late 1950s as the serum inhibitor of C1 esterase (Levy and Lepow 1959). Today we know that it inhibits other serine proteases in various enzymatic systems. When the levels of C1-INH fall below 50% of normal, the contact system is exposed to inappropriate activation with local release of bradykinin, increase of endothelial permeability, fluid extravasation, and edema formation (Fig. 1). The most common cause of C1-INH deficiency are mutations in its coding gene SERPING1. An acquired deficiency of C1-INH, with identical clinical features, has also been described (Caccia et al. 2014). Genetic deficiency of C1-INH with angioedema symptoms (C1-INH-HAE) has a prevalence around 1:50,000...

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Institutional subscriptions

References

  • Bafunno V, Divella C, Sessa F, Tiscia GL, Castellano G, Gesualdo L, et al. De novo homozygous mutation of the C1 inhibitor gene in a patient with hereditary angioedema. J Allergy Clin Immunol. 2013;132:748.

    Article  CAS  PubMed  Google Scholar 

  • Banerji et al. Inhibiting plasma kallikrein for hereditary angioedema prophylaxis. N Engl J Med. 2017;376:717–28.

    Google Scholar 

  • Bhardwaj N, Craig TJ. Treatment of hereditary angioedema: a review. Transfusion. 2014;54:2989.

    Article  CAS  PubMed  Google Scholar 

  • Bork K, Hardt J, Witzke G. Fatal laryngeal attacks and mortality in hereditary angioedema due to C1-INH deficiency. J Allergy Clin Immunol. 2012;130(3):692–7.

    Article  PubMed  Google Scholar 

  • Bork K. Pasteurized and nanofiltered, plasma-derived C1 esterase inhibitor concentrate for the treatment of hereditary angioedema. Immunotherapy. 2014;6(5):533–51.

    Article  CAS  PubMed  Google Scholar 

  • Caccia S, Suffritti C, Cicardi M. Pathophysiology of hereditary angioedema. Pediatr Allergy Immunol Pulmonol. 2014;27(4):159–63.

    Article  PubMed  PubMed Central  Google Scholar 

  • Cumming SA, Halsall DJ, Ewan PW, Lomas DA. The effect of sequence variations within the coding region of the C1 inhibitor gene on disease expression and protein function in families with hereditary angio-oedema. J Med Genet. 2003;40(10):e114.

    Article  PubMed  PubMed Central  Google Scholar 

  • Farkas H. Current pharmacotherapy of bradykinin-mediated angioedema. Expert Opin Pharmacother. 2013;14(5):571–86.

    Article  CAS  PubMed  Google Scholar 

  • Kaplan AP, Joseph K. Pathogenic mechanisms of bradykinin mediated diseases: dysregulation of an innate inflammatory pathway. Adv Immunol. 2014;121:41–89.

    Article  CAS  PubMed  Google Scholar 

  • Levy LR, Lepow IH. Assay and properties of serum inhibitor of C'l-esterase. Proc Soc Exp Biol Med. 1959;101:608–11.

    Article  CAS  PubMed  Google Scholar 

  • Longhurst H, Cicardi M. Hereditary angio-oedema. Lancet. 2012;379(9814):474–81.

    Article  PubMed  Google Scholar 

  • Longhurst et al. Prevention of hereditary angioedema attacks with subcutaneous C1 inhibitor. N Engl J Med. 2017;376:1131–40.

    Google Scholar 

  • Mansi M, Zanichelli A, Coerezza A, Suffritti C, Wu MA, Vacchini R, et al. Presentation, diagnosis and treatment of angioedema without wheals: a retrospective analysis of a cohort of 1058 patients. J Intern Med. 2015;277(5):585–93.

    Article  CAS  PubMed  Google Scholar 

  • Nussberger J, Cugno M, Cicardi M. Bradykinin-mediated angioedema. N Engl J Med. 2002;347(8):621–2.

    Article  PubMed  Google Scholar 

  • Riedl MA. Critical appraisal of androgen use in hereditary angioedema: a systematic review. Ann Allergy Asthma Immunol. 2015;114(4):281–8. e7

    Article  CAS  PubMed  Google Scholar 

  • Tosi M, Carugati A, Hernandez C, Boucontet L, Pappalardo E, Agostoni A, et al. De novo C1 inhibitor mutations in hereditary angioedema. Mol Immunol. 1998;35(6–7):406.

    Article  Google Scholar 

  • Zanichelli A, Arcoleo F, Barca MP, Borrelli P, Bova M, Cancian M, et al. A nationwide survey of hereditary angioedema due to C1 inhibitor deficiency in Italy. Orphanet J Rare Dis. 2015;10:11.

    Article  PubMed  PubMed Central  Google Scholar 

  • Zuraw BL, Cicardi M, Longhurst HJ, Bernstein JA, Li HH, Magerl M, et al. Phase II study results of a replacement therapy for hereditary angioedema (HAE) with subcutaneous C1-inhibitor concentrate. Allergy. 2015;70:1319.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Marco Cicardi .

Editor information

Editors and Affiliations

Section Editor information

Rights and permissions

Reprints and permissions

Copyright information

© 2016 Springer Science+Business Media LLC

About this entry

Cite this entry

Cicardi, M., Zanichelli, A., Suffritti, C., Wu, M., Caccia, S. (2016). Hereditary Deficiency of C1 Inhibitor and Angioedema. In: MacKay, I., Rose, N. (eds) Encyclopedia of Medical Immunology. Springer, New York, NY. https://doi.org/10.1007/978-1-4614-9209-2_4-1

Download citation

  • DOI: https://doi.org/10.1007/978-1-4614-9209-2_4-1

  • Received:

  • Accepted:

  • Published:

  • Publisher Name: Springer, New York, NY

  • Print ISBN: 978-1-4614-9209-2

  • Online ISBN: 978-1-4614-9209-2

  • eBook Packages: Springer Reference MedicineReference Module Medicine

Publish with us

Policies and ethics